Press Releases

Read our latest announcements below!

news-icon

Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

Mustang Bio, Inc. and Minaris Regenerative Medicine GmbH have announced they have signed an agreement to enable technology transfer and GMP clinical manufacturing of MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in Europe.

Read Press Release 

news-icon

Minaris Regenerative Medicine to Significantly Expand Manufacturing Capacity for Cell and Gene Therapies in Germany and Japan

Minaris Regenerative Medicine announced today a total 64.5 million USD to significantly expand its facilities in Europe and Asia. 

Read Press Release 

news-icon

Hitachi Chemical's Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine

The regenerative medicine business of Hitachi Chemical Co., Ltd. announces that it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.

Read Press Release